Breaking News
Investing Pro 0
NEW! Get Actionable Insights with InvestingPro+ Try 7 Days Free

Citius Pharma Inks Clinical Collaboration For I/ONTAK Combo Regime in Solid Tumor Settings

Stock Markets Sep 23, 2022 12:40
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. Citius Pharma Inks Clinical Collaboration For I/ONTAK Combo Regime in Solid Tumor Settings
 
CTXR
+2.70%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

  • Citius Pharmaceuticals Inc (NASDAQ: CTXR) collaborated with the University of Pittsburgh for I/ONTAK (denileukin diftitox or E7777) in combination with Merck & Company, Inc. (NYSE: MRK) Keytruda (pembrolizumab) for recurrent or metastatic solid tumors.
  • The investigator-initiated trial at UPMC is an open-label, Phase 1/1b study consisting of two parts.
  • Part I is a dose escalation study of four cohorts and is expected to enroll 18-30 patients.
  • Part 2 is a dose expansion study of approximately 40 patients to evaluate the safety and tolerability of the recommended combination dose of I/ONTAK and pembrolizumab.
  • Related: Citius Pharma To Spinoff Late-Stage Oncology Asset Into New Publicly Traded Firm.
  • The study will also investigate the alteration of the immune microenvironment within tumors and peripheral blood.
  • Secondary endpoints include the objective response (complete response plus partial response), progression-free survival, and overall survival.
  • University of Pittsburgh dose-ranging study is expected to begin in the fourth quarter of 2022.
  • Additionally, Citius is collaborating with an investigator-initiated study at the University of Minnesota (UMN).
  • This Phase 1 dose-finding study to evaluate I/ONTAK before Novartis AG's (NYSE: NVS) Kymriah (tisagenleucel) CAR-T therapy for diffuse large B-cell lymphoma (DLBCL) enrolled its first patient in May 2021.
  • Price Action: CTXR shares closed 6.84% higher at $1.25 during after-hours trading on Thursday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Citius Pharma Inks Clinical Collaboration For I/ONTAK Combo Regime in Solid Tumor Settings
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email